BioCentury
ARTICLE | Clinical News

IW001: Preliminary Phase I data

December 3, 2012 8:00 AM UTC

Preliminary data from an open-label, U.S. Phase I trial in 30 patients with IPF showed that once-daily 0.1, 0.5 and 1 mg doses of IW001 for 24 weeks were well tolerated. There were no changes in lung ...